The specific blockade of the CD155 interaction with multiple inhibitory receptors expressed on NK and T lymphocytes, such as TIGIT, killer-cell immunoglobulin-like receptor (KIR) KIR2DL5 and CD96 [67], are now being explored in various types of cancer [10]. Here, PVR is linked to cancer.